Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (Nasdaq: HYPR) reported growing adoption of its FDA-cleared, AI-powered portable brain MRI, the Swoop system, in neurology offices, highlighted by the peer-reviewed publication of the NEURO PMR study in the Journal of Neuroimaging and more than 3,000 in-office brain MRI scans in the first year of its office-market launch.
According to Hyperfine, NEURO PMR is the first prospective, multicenter, real-world study of portable MRI versus high-field MRI in outpatient neurology. Portable MRI showed 92% concordance with high-field MRI for structural abnormalities in blinded review, 98% with clinical information, and a four-to-one patient preference, while being deployable in standard exam rooms and used across varied neurology and brain health practices.
Hyperfine (Nasdaq: HYPR) received FDA clearance for its latest Optive AI™ software update for the Swoop® portable brain MRI system. This is the second FDA-cleared software package since the next-generation Swoop launch in mid-2025.
The new software enhances image quality across all Swoop sequences, improves proprietary noise correction in electromagnetically noisy care settings, and introduces a more guided, intuitive scanning workflow. It also debuts an isotropic T1 sequence for three-dimensional visualization and thinner slices, aimed at strengthening clinical utility in uses such as post-operative tumor follow-up. Hyperfine plans to begin rolling out the software in the United States to existing and new Swoop users in September.
Hyperfine (Nasdaq: HYPR) reported second quarter 2026 revenue of $3.9 million, up 44.8% from $2.7 million a year earlier, driven by sales of 12 Swoop® systems, a 50.0% increase. Gross profit was $2.0 million with gross margin of 50.7%, up from 49.3%.
Research and development expenses fell 14.9% to $3.9 million, while sales, marketing, general and administrative costs rose 3.2% to $6.6 million. Net loss was $9.3 million, or -$0.09 per share. Cash and cash equivalents were $43.5 million on June 30, 2026, supported by $25.3 million of first-half financing, including $13.6 million debt and $11.4 million at-the-market equity issuance.
The company obtained CE Mark and UKCA approval for the next-generation Swoop® system and Optive AI™ software, launched the next-generation Swoop® in Europe, and highlighted PRIME study data showing portable MRI reduced emergency department time to imaging. Full-year 2026 revenue guidance of $20–$22 million and cash burn guidance of $26–$28 million were reiterated.
Hyperfine (Nasdaq: HYPR) announced multiple new peer-reviewed publications supporting its FDA-cleared, AI-powered portable brain MRI, the Swoop® system, in neurosurgical and stroke care settings. New reports in the Journal of Neurosurgery describe ambulatory neurosurgery cases where Swoop imaging immediately after endovascular procedures helped confirm absence of acute ischemia or intracranial hemorrhage and enabled same-day discharge.
In addition, a Stroke journal collection reviews existing and new evidence on low-field MRI across the stroke continuum, from pre-hospital care to neurocritical care and cerebral small vessel disease, and offers implementation guidance. According to Hyperfine, Swoop is now supported by more than 180 peer-reviewed publications and editorials and over 280 scientific presentations across multiple sites of care.
Hyperfine (Nasdaq: HYPR) announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026. The company, known for the first FDA-cleared AI-powered portable brain MRI, will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results.
A live audio webcast and an archived recording will be available on the Investors page of Hyperfine’s website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the call. Additional information on the Swoop system is available at HyperfineMRI.com.
Hyperfine (Nasdaq: HYPR) launched its next-generation Swoop® portable MRI (Model 2) in Europe, powered by updated Optive AI™ software. Following CE mark and UKCA approvals, the system is commercially available in initial European markets and listed on France’s UniHA procurement platform, supporting the company’s 2026 international commercialization strategy.
Hyperfine (Nasdaq: HYPR) formed a Global Neurosurgery Advisory Council to support expansion of its Swoop® portable, ultra-low-field, AI-powered brain MRI system in neurosurgical care.
The multidisciplinary group of leading neurosurgeons will guide workflow integration, product development, and clinical evidence generation across preoperative, intraoperative, and postoperative settings.
Hyperfine (Nasdaq: HYPR) reported record U.S. scan volumes for its FDA-cleared AI-powered portable brain MRI, the Swoop® system, across hospitals and neurology clinics.
Key sites surpassed 1,000 and 500-scan milestones, showing expanding clinical use in ICUs, EDs, operating rooms, and outpatient neurology practices, with reported benefits in patient access, wait times, and hospital efficiency.
Hyperfine (Nasdaq: HYPR), developer of the FDA-cleared AI-powered portable brain MRI Swoop system, is expected to join the Russell 3000 and Russell 2000 indexes after the U.S. market close on June 26, 2026, following the June 2026 Russell reconstitution.
Membership in the Russell 3000 is set for six months under the new semi-annual schedule. Russell U.S. indexes are widely used benchmarks, with about $12.2 trillion in assets linked to them as of June 2025.
Hyperfine (Nasdaq: HYPR) reported results from the single-center randomized PRIME study of its Swoop portable MRI in emergency departments.
Portable MRI reduced median order-to-scan time to 1.28 hours vs 7.76 hours, detected critical pathology in 18.6% of scans, and all findings were confirmed on conventional MRI.